November 30th 2023
Here are some updates from the world of psychiatry throughout the month of November.
November 17th 2023
What is new in research on psychedelics?
November 11th 2023
From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.
November 10th 2023
What is new in research on dementia?
November 6th 2023
New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.
Deep Dive on Dementia at the 2023 Psychiatric Times World CME Conference
Don't miss the the 2023 Psychiatric Times World CME conference, where our Editor in Chief will present on the 14 different types of dementia!
Sleep Research Roundup: September 29
What is new in research on sleep?
Antipsychotic Medication for Parkinson Disease Psychosis Receives Packaging Label Updates
The drug’s developer announced that the FDA has made 2 clarifying revisions.
Special Populations Research Roundup: September 15
What is new in research on psychiatric care for Latinx patient populations?
ADHD Research Roundup: September 8
What is new in research on attention-deficit/hyperactivity disorder?
The Week in Review: July 17-21
From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.
Study Supports Neuroprotective, Disease-Modifying Effects of Clinical Drug Candidate in the Treatment of Alzheimer Disease
“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”
Experimental Drug Slows Progression of Alzheimer Disease in Patients With Mild Impairment by 60%
Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.
Dementia Treatment: An Unmet Need
"There is clearly a large unmet need not only to improve our treatment of AD, but to provide treatment options for all the dementias."
The Week in Review: July 3-7
From the FDA traditional approval of Leqembi to an examination of how we can improve mental health care for women of color, here are highlights from the week in Psychiatric Times.
FDA Grants Traditional Approval to Leqembi for the Treatment of Alzheimer Disease
Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.
The Week in Review: May 29-June 2
From substance use among adolescents and young adults to managing behavioral and psychological symptoms of dementia, here are highlights from the week in Psychiatric Times.
Understanding and Managing Behavioral and Psychological Symptoms of Dementia
Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.
The Week in Review: May 8-12
From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.
FDA Approves First Treatment for Agitation Associated With Alzheimer Disease Dementia
Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.
The Week in Review: April 24-28
From connections between bvFTD and primary psychiatric disorders to the impact of posttraumatic neuroendocrine dysfunction on recovery, here are highlights from the week in Psychiatric Times.
The Border Zone Between bvFTD and Primary Psychiatric Disorders
In this CME, learn more about frontotemporal lobar degeneration and the several overlapping syndromes that it encompasses, as well as how to distinguish behavioral variant frontotemporal lobar degeneration from other psychiatric disorders.
The Week in Review: April 17-21
From eating disorders in entertainment to early intervention for schizophrenia, here are highlights from the week in Psychiatric Times.
Progress Made Toward the Approval of Treatment of Agitation Associated With Alzheimer Dementia
If approved, the drug will be the first FDA-approved treatment for agitation associated with Alzheimer dementia in the United States.
The Whole Package
"It is amazing how much we know about the magnificent brain—and how much we have yet to learn."
From the Pages of Psychiatric Times: March 2023
The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.
Lewy Body Dementia: Unpacking a Neuropsychiatric Enigma
In this CME, learn the current criteria, unique diagnostic biomarkers, and differential diagnosis of Lewy body dementia.
The Week in Review: March 6-10
From Alzheimer disease treatments to the psychiatric implications of conspiracy theories, here are highlights from the week in Psychiatric Times.
The Clock-Drawing Test
A look at one of the most informative yet easy-to-administer tests for assessing brain dysfunction.
Lithium and Medical Comorbidity
Researchers performed a nationwide register-based cohort study of patients treated with lithium in Finland.
Lithium: A Narrative Overview and Future Frontiers
Lithium: what’s its history and where do we still need more information?
The Week in Review: December 19-23
From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.
The Importance of Cherishing the Older Adults in Your Life
"Dementia is a mental health condition that can make or break families. Remember that behind the difficult behavior is your loved one."
Dementia in the News
What's the latest in dementia?
Exploring the New Era of Hope and Possibilities for Patients With Dementia
"To be sure, we are still in the nascent stages of developing treatments. However, our armamentarium is steadily growing."
2 Clarke Drive Cranbury, NJ 08512